| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.6 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |